Pfizer and Antex Initiate Collaboration
GAITHERSBURG, Md., Sept. 29 /PRNewswire/ -- Antex Biologics Inc. announces a collaboration with Pfizer Inc.
"We are pleased to be working with Pfizer Inc., one of the foremost global pharmaceutical companies and one of the world's leaders in animal health products," said Theresa M. Stevens, Antex's Vice President, Corporate Development. "While specifics of the collaboration will not be disclosed, we are encouraged that Antex's proprietary platform technologies are now being applied to the development of animal vaccines."
Antex's platform technologies, ART(TM) (Antigen Receptor Technology) and NST(TM) (Nutriment Signal Transduction), have been used initially to develop human vaccines. Already, strategic collaborations have been established with the world's two leading vaccine companies, SmithKline Beecham and Pasteur Merieux Connaught. Three of Antex's human vaccines are in clinical development. Additionally, these platform technologies have provided AntexPharma, Antex's pharmaceutical wholly-owned subsidiary, with discoveries including novel antibiotic targets and new chemical entities.
Ms. Stevens continued, "Animals are prone to many bacterial infections. There is a great need for the development of new vaccines and antibiotics to treat and prevent them. We see this collaboration as an important step toward our long-range business strategy (1) to leverage Antex's expertise in infectious diseases and (2) to apply our proprietary technologies toward developing products for not only human, but also animal health. Given our successes to date in developing novel human vaccines, we are encouraged that our expertise will be successfully applied to animal vaccines as well."
Antex Biologics is a biopharmaceutical company committed to improving health by developing new products to prevent and treat infections and related diseases. The Company's common stock is quoted on the OTC Bulletin Board under the ticker symbol ANTX. |
